Safe and effective health products for Canadians: New authorizations between July and September 2026

Canadians expect timely access to safe and effective drugs and medical devices. Health Canada is providing a quarterly update on the steps the department is taking to make its regulatory processes more modern and efficient, while maintaining high standards for safety, efficacy, and quality.

October 15, 2026 | Ottawa, Ontario | Health Canada

Canadians expect timely access to safe and effective drugs and medical devices. Health Canada is providing a quarterly update on the steps the department is taking to make its regulatory processes more modern and efficient, while maintaining high standards for safety, efficacy, and quality.

From July 1 to September 30, 2026, Health Canada has taken a number of steps to improve access to the drugs and medical devices Canadians need. The department has authorized 16 new prescription drugs and 33 generic and biosimilar drugs. During this period, Health Canada also approved 540 new medical devices. 

A growing number of increasingly complex drug submissions is putting pressure on the drug review process. To address this, Health Canada is prioritizing the review of certain generic drug submissions to provide better access to medicines in Canada, prevent and minimize disruptions to Canada’s drug supply, and make the generic drug review system more sustainable in the long term.

To help Canadians access promising new treatments sooner, Health Canada is also moving forward with the first phase of its clinical trials modernization efforts. This includes :